Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera

by Tamir, Hadas , Achdout, Hagit , Paran, Nir , Fisher, Morly , Politi, Boaz , Zichel, Ran , Cohen-Gihon, Inbar , Weiss, Shay , Izak, Marina , Mandelboim, Michal , Mechaly, Adva , Erez, Noam , Madar-Balakirski, Noa , Cohen, Daniel , Marcus, Hadar , Beth-Din, Adi , Melamed, Sharon , Israely, Tomer , Yahalom-Ronen, Yfat , Glinert, Itai , Israeli, Ofir , Shinar, Eilat , Caraco, Yoseph , Zvi, Anat

in Amino acids / Antibodies / Antibody response / Bioinformatics / Brief Report / BriLife / Clinical trials / Coronaviruses / COVID-19 / COVID-19 vaccines / Genomes / Infections / Mutation / Neutralization / Pandemics / Proteins / SARS-CoV-2 / Severe acute respiratory syndrome coronavirus 2 / Software / Stomatitis / vaccine / Vaccine efficacy / Vaccines / variants / Viral diseases / Viruses / VOC

2022

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera

2022

Confirm

Do you wish to request the book?

Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera

2022

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera

Tamir, Hadas,

Achdout, Hagit,

Paran, Nir,

Fisher, Morly,

Politi, Boaz,

Zichel, Ran,

Cohen-Gihon, Inbar,

Weiss, Shay,

Izak, Marina,

Mandelboim, Michal,

Mechaly, Adva,

Erez, Noam,

Madar-Balakirski, Noa,

Cohen, Daniel,

Marcus, Hadar,

Beth-Din, Adi,

Melamed, Sharon,

Israely, Tomer,

Yahalom-Ronen, Yfat,

Glinert, Itai,

Israeli, Ofir,

Shinar, Eilat,

Caraco, Yoseph,

Zvi, Anat

2022

Overview

The emergence of rapidly spreading variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a major challenge to the ability of vaccines and therapeutic antibodies to provide immunity. These variants contain mutations of specific amino acids that might impede vaccine efficacy. BriLife® (rVSV-ΔG-spike) is a newly developed SARS-CoV-2 vaccine candidate currently in phase II clinical trials. It is based on a replication-competent vesicular stomatitis virus (VSV) platform. The rVSV-ΔG-spike contains several spontaneously acquired spike mutations that correspond to SARS-CoV-2 variants’ mutations. We show that human sera from BriLife® vaccinees preserve comparable neutralization titers towards alpha, gamma, and delta variants and show less than a three-fold reduction in the neutralization capacity of beta and omicron compared to the original virus. Taken together, we show that human sera from BriLife® vaccinees overall maintain a neutralizing antibody response against all tested variants. We suggest that BriLife®-acquired mutations may prove advantageous against future SARS-CoV-2 VOCs.

Share this book

Add to My Shelf

Publisher

MDPI AG,MDPI

Subject

/ BriLife